KOPRAN2024-10-012024-12-31 KOPRAN2024-10-012024-12-31 KOPRAN2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member KOPRAN2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member KOPRAN2024-12-31 KOPRAN2024-10-012024-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member KOPRAN2024-10-012024-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member KOPRAN2024-10-012024-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member KOPRAN2024-10-012024-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524280 KOPRAN NOTLISTED Kopran Limited Equity 2024-04-01 2025-03-31 2025-02-11 2025-02-04 INR Lakhs Third quarter 14:00:00 15:15:00 2025-02-11 2025-02-11 Not applicable Single segment Pharmaceuticals 2024-10-01 2024-12-31 Unaudited Consolidated 1662429000.00 1717000.00 1664146000.00 967509000.00 4164000.00 85375000.00 153968000.00 21558000.00 39968000.00 253018000.00 1525560000.00 138586000.00 0.00 138586000.00 31726000.00 2909000.00 34635000.00 0.00 103951000.00 0.00 0.00 0.00 0.00 103951000.00 1145000.00 105096000.00 103951000.00 0.00 218115000.00 0.00 482494000.00 10 0.00 0.00 0.00 0.00 0.00 0.00 Notes 1) The above Statement of consolidated and standalone unaudited financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act 2013, read with Companies (Indian Accounting Standards) Rules, 2015, as amended and other accounting principles generally accepted in India. There is no minority interest. 2) The above Statement of consolidated and standalone unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 11, 2025 and have been reviewed by the Statutory Auditors of the Company who have expressed unmodified opinion. 3) The Company and the subsidiaries together referred to as Group are engaged primarily in the Pharmaceuticals business and there are no separate reportable segments as per Ind AS 108 on Operating Segment Reporting . 4) During the quarter ended December 31, 2024, the Company has allotted 38,800 equity shares of Rs. 10 each fully paid up, on exercise of stock options by employees in accordance with the Company's Kopran Employee Stock Option Plan 2023. 5) Figures for the previous period have been regrouped or reclassified, wherever necessary to make them comparable with the figures of the current period. Single segment 2024-04-01 2024-12-31 Unaudited Consolidated 4572413000.00 15198000.00 4587611000.00 2918041000.00 18910000.00 -44396000.00 432744000.00 65717000.00 117255000.00 696971000.00 4205242000.00 382369000.00 0.00 382369000.00 89020000.00 4603000.00 93623000.00 0.00 288746000.00 0.00 0.00 0.00 0.00 288746000.00 2023000.00 290769000.00 288746000.00 0.00 292792000.00 0.00 482494000.00 10 0.00 0.00 0.00 0.00 0.00 0.00 Other expenses 253018000.00 Other expenses 696971000.00 Remeasurements oof defined benefit plans 544000.00 Remeasurements oof defined benefit plans 1634000.00 544000.00 1634000.00 138000.00 410000.00 Exchange difference in translating the financial statements of foreign operation 739000.00 Exchange difference in translating the financial statements of foreign operation 799000.00 739000.00 799000.00 0.00 0.00